Inventor · disambiguated record
Ruvo Menotti
Also filed as: MENOTTI RUVO
1 granted patent·9 pending applications·13 citations·filing 2002–2013
44Inventor score
Technology areasA61P
Top patents by PatentIndex Score
10 records- 0181US7482004B2Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakageVLAAMS INTERUNIV INST BIOTECH·Filed 2002·Granted Jan 27, 2009·13 cites·9 claims
- 0265US2009238826A1Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakageVLAAMS INTERUNIV INST BIOTECH·Filed 2009·Application pending·0 cites
- 0364US2009074765A1Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakageVLAAMS INTERUNIV INST BIOTECH·Filed 2008·Application pending·0 cites
- 0464US2009162354A1Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakageVLAAMS INTERUNIV INST BIOTECH·Filed 2008·Application pending·0 cites
- 0555US2013177565A1Administering anti-placental growth factor antibodiesCARMELIET PETER·Filed 2013·Application pending·0 cites
- 0655US2013183310A1Administering anti-placental growth factor antibodiesCARMELIET PETER·Filed 2013·Application pending·0 cites
- 0755US2013177564A1Administering anti-placental growth factor antibodiesCARMELIET PETER·Filed 2013·Application pending·0 cites
- 0854US2012263710A1Administering anti-placental growth factor antibodiesCARMELIET PETER·Filed 2012·Application pending·0 cites
- 0941US2013203685A1Protease targeting agentsCONSIGLIO NAZIONALE RICERCHE·Filed 2013·Application pending·0 cites
- 1037US2011275569A1Proteases targeting agentsCONSIGLIO NAZIONALE RICERCHE·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →